Drug Trial Radar · NCT05707676
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors(MEETCD8-001)
Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
40
Actual
Start
Nov 30, 2022
Primary completion
Dec 20, 2024
Study completion Dec 20, 2024
Sponsor
- Lead sponsor
- L & L Bio Co., Ltd., Ningbo, ChinaIndustry
- Sponsor type
- Industry
- First posted
- Feb 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I study designed to evaluate if LB4330, an anti-Claudin 18.2 and CD8 T cell activator fusion protein, is safe, tolerable and efficacious in participants with Advanced Solid Tumors
Conditions
- Solid Tumor
Interventions
LB4330Drug
LB4330
Primary outcomes
What the sponsor says the trial is designed to measure.
- MTD/RP2DTime frame: up to study completion,approximately 24 months
- DLT occurrence and frequency (dose escalation phase)Time frame: The first period of LB4330 treatment (28 days for the first subject in the first dose group, 21 days for the rest subjects. If the administration is delayed, the DLT evaluation period should be extended to 7 days after the third administration)
- AE, SAE occurrence and frequency (according to NCI CTCAE 5.0)Time frame: up to 90 days following last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.